Zofenopril calcium

Suppliers

Names

[ CAS No. ]:
81938-43-4

[ Name ]:
Zofenopril calcium

[Synonym ]:
Calcium bis[(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)-2-pyrrolidinecarboxylate]
ZOFENOPRIL CALCIUM
Calcium bis[(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylate]
L-Proline, 1-[(2S)-3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, calcium salt, (4S)- (2:1)
MFCD08704648
Zofenopril calcium salt

Chemical & Physical Properties

[ Density]:
1.34 g/cm3

[ Boiling Point ]:
646.3ºC at 760 mmHg

[ Melting Point ]:
>250ºC

[ Molecular Formula ]:
C₂₂H₂₂Ca_0.5NO₄S₂

[ Molecular Weight ]:
448.58

[ Flash Point ]:
344.7ºC

[ PSA ]:
228.56000

[ LogP ]:
7.80660

[ Storage condition ]:
Refrigerator

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H410

[ Precautionary Statements ]:
P273-P501

[ Hazard Codes ]:
N

[ Risk Phrases ]:
50/53

[ Safety Phrases ]:
60-61

[ RIDADR ]:
UN 3077 9 / PGIII

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Articles

Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions.

Cardiovasc. Ther. 27(4) , 275-88, (2009)

Zofenopril, is a highly lipophilic ACE inhibitor, characterized by long-lasting tissue penetration and sustained cardiac ACE inhibition, indicated for the treatment of hypertension and myocardial infa...

Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of zofenopril and its active metabolite zofenoprilat in human plasma.

J. Pharm. Biomed. Anal. 55(3) , 527-32, (2011)

A novel, sensitive and rapid liquid chromatographic-electrospray ionization mass spectrometric method was developed and validated for the determination of zofenopril and its active metabolite zofenopr...

Effects of zofenopril and ramipril on cough reflex responses in anesthetized and awake rabbits.

J. Cardiovasc. Pharmacol. Ther. 15(4) , 384-92, (2010)

Cough is the most common symptom reported by patients in a primary care setting and is one of the most frequent secondary effects recorded during treatment with angiotensin-converting enzyme (ACE) inh...